Diagnosis and monitoring of human cytomegalovirus infection in transplant recipients

Giuseppe Gerna, Fausto Baldanti, Paolo Grossi, Franco Locatelli, Paolo Colombo, Mario Viganò, M. Grazia Revello

Research output: Contribution to journalArticle

Abstract

In the last decade, transplantology has become the treatment of choice for a large number of malignant diseases or organ dysfunctions. Transplants are classified into two main groups: solid organ transplants (SOT) and haematopoietic stem cell transplants (HSCT). Human cytomegalovirus (HCMV) infection is the most common viral complication in both SOT and HSCT recipients within 3 months of transplant. Major risk factors for HCMV infection are the mismatch between donor and recipient antibody status, and the immunosuppressive regimen. Clinical manifestations range from asymptomatic infections to severe HCMV disease involving lung, gastrointestinal tract, liver, retina, central and peripheral nervous systems. Diagnosis is based mainly upon detection and quantification of virus in blood by determination of viraemia, antigenaemia, DNAaemia, and RNAaemia. In addition, detection of the emergence of resistance to HCMV-specific antiviral drugs such as ganciclovir and foscarnet, may be achieved by performing phenotypic and genotypic assays. Monitoring of HCMV infections in both SOT and HSCT recipients allows timely adoption of pre-emptive (presymptomatic) therapy strategies, which have led to almost complete disappearance of HCMV disease in both transplantation settings. In parallel, sustained treatment with specific antiviral drugs must elicit monitoring of antiviral drug resistance to permit a timely shift to an alternative drug. In conclusion, diagnostic and therapeutic tools now available allow almost complete control of HCMV infections in different transplantation settings.

Original languageEnglish
Pages (from-to)155-175
Number of pages21
JournalReviews in Medical Microbiology
Volume12
Issue number3
Publication statusPublished - 2001

Fingerprint

Cytomegalovirus Infections
Transplants
Hematopoietic Stem Cells
Cytomegalovirus
Antiviral Agents
Viral Drug Resistance
Transplantation
Foscarnet
Ganciclovir
Asymptomatic Infections
Transplant Recipients
Viremia
Peripheral Nervous System
Therapeutics
Immunosuppressive Agents
Lung Diseases
Retina
Gastrointestinal Tract
Central Nervous System
Tissue Donors

Keywords

  • Antiviral drug resistance
  • Bone marrow transplant
  • Diagnosis
  • Human cytomegalovirus
  • Pre-emptive therapy
  • Solid-organ transplant

ASJC Scopus subject areas

  • Microbiology (medical)
  • Microbiology

Cite this

Diagnosis and monitoring of human cytomegalovirus infection in transplant recipients. / Gerna, Giuseppe; Baldanti, Fausto; Grossi, Paolo; Locatelli, Franco; Colombo, Paolo; Viganò, Mario; Revello, M. Grazia.

In: Reviews in Medical Microbiology, Vol. 12, No. 3, 2001, p. 155-175.

Research output: Contribution to journalArticle

Gerna, Giuseppe ; Baldanti, Fausto ; Grossi, Paolo ; Locatelli, Franco ; Colombo, Paolo ; Viganò, Mario ; Revello, M. Grazia. / Diagnosis and monitoring of human cytomegalovirus infection in transplant recipients. In: Reviews in Medical Microbiology. 2001 ; Vol. 12, No. 3. pp. 155-175.
@article{5ff3f300d4294795b956f4e1638d0779,
title = "Diagnosis and monitoring of human cytomegalovirus infection in transplant recipients",
abstract = "In the last decade, transplantology has become the treatment of choice for a large number of malignant diseases or organ dysfunctions. Transplants are classified into two main groups: solid organ transplants (SOT) and haematopoietic stem cell transplants (HSCT). Human cytomegalovirus (HCMV) infection is the most common viral complication in both SOT and HSCT recipients within 3 months of transplant. Major risk factors for HCMV infection are the mismatch between donor and recipient antibody status, and the immunosuppressive regimen. Clinical manifestations range from asymptomatic infections to severe HCMV disease involving lung, gastrointestinal tract, liver, retina, central and peripheral nervous systems. Diagnosis is based mainly upon detection and quantification of virus in blood by determination of viraemia, antigenaemia, DNAaemia, and RNAaemia. In addition, detection of the emergence of resistance to HCMV-specific antiviral drugs such as ganciclovir and foscarnet, may be achieved by performing phenotypic and genotypic assays. Monitoring of HCMV infections in both SOT and HSCT recipients allows timely adoption of pre-emptive (presymptomatic) therapy strategies, which have led to almost complete disappearance of HCMV disease in both transplantation settings. In parallel, sustained treatment with specific antiviral drugs must elicit monitoring of antiviral drug resistance to permit a timely shift to an alternative drug. In conclusion, diagnostic and therapeutic tools now available allow almost complete control of HCMV infections in different transplantation settings.",
keywords = "Antiviral drug resistance, Bone marrow transplant, Diagnosis, Human cytomegalovirus, Pre-emptive therapy, Solid-organ transplant",
author = "Giuseppe Gerna and Fausto Baldanti and Paolo Grossi and Franco Locatelli and Paolo Colombo and Mario Vigan{\`o} and Revello, {M. Grazia}",
year = "2001",
language = "English",
volume = "12",
pages = "155--175",
journal = "Reviews in Medical Microbiology",
issn = "0954-139X",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Diagnosis and monitoring of human cytomegalovirus infection in transplant recipients

AU - Gerna, Giuseppe

AU - Baldanti, Fausto

AU - Grossi, Paolo

AU - Locatelli, Franco

AU - Colombo, Paolo

AU - Viganò, Mario

AU - Revello, M. Grazia

PY - 2001

Y1 - 2001

N2 - In the last decade, transplantology has become the treatment of choice for a large number of malignant diseases or organ dysfunctions. Transplants are classified into two main groups: solid organ transplants (SOT) and haematopoietic stem cell transplants (HSCT). Human cytomegalovirus (HCMV) infection is the most common viral complication in both SOT and HSCT recipients within 3 months of transplant. Major risk factors for HCMV infection are the mismatch between donor and recipient antibody status, and the immunosuppressive regimen. Clinical manifestations range from asymptomatic infections to severe HCMV disease involving lung, gastrointestinal tract, liver, retina, central and peripheral nervous systems. Diagnosis is based mainly upon detection and quantification of virus in blood by determination of viraemia, antigenaemia, DNAaemia, and RNAaemia. In addition, detection of the emergence of resistance to HCMV-specific antiviral drugs such as ganciclovir and foscarnet, may be achieved by performing phenotypic and genotypic assays. Monitoring of HCMV infections in both SOT and HSCT recipients allows timely adoption of pre-emptive (presymptomatic) therapy strategies, which have led to almost complete disappearance of HCMV disease in both transplantation settings. In parallel, sustained treatment with specific antiviral drugs must elicit monitoring of antiviral drug resistance to permit a timely shift to an alternative drug. In conclusion, diagnostic and therapeutic tools now available allow almost complete control of HCMV infections in different transplantation settings.

AB - In the last decade, transplantology has become the treatment of choice for a large number of malignant diseases or organ dysfunctions. Transplants are classified into two main groups: solid organ transplants (SOT) and haematopoietic stem cell transplants (HSCT). Human cytomegalovirus (HCMV) infection is the most common viral complication in both SOT and HSCT recipients within 3 months of transplant. Major risk factors for HCMV infection are the mismatch between donor and recipient antibody status, and the immunosuppressive regimen. Clinical manifestations range from asymptomatic infections to severe HCMV disease involving lung, gastrointestinal tract, liver, retina, central and peripheral nervous systems. Diagnosis is based mainly upon detection and quantification of virus in blood by determination of viraemia, antigenaemia, DNAaemia, and RNAaemia. In addition, detection of the emergence of resistance to HCMV-specific antiviral drugs such as ganciclovir and foscarnet, may be achieved by performing phenotypic and genotypic assays. Monitoring of HCMV infections in both SOT and HSCT recipients allows timely adoption of pre-emptive (presymptomatic) therapy strategies, which have led to almost complete disappearance of HCMV disease in both transplantation settings. In parallel, sustained treatment with specific antiviral drugs must elicit monitoring of antiviral drug resistance to permit a timely shift to an alternative drug. In conclusion, diagnostic and therapeutic tools now available allow almost complete control of HCMV infections in different transplantation settings.

KW - Antiviral drug resistance

KW - Bone marrow transplant

KW - Diagnosis

KW - Human cytomegalovirus

KW - Pre-emptive therapy

KW - Solid-organ transplant

UR - http://www.scopus.com/inward/record.url?scp=0034909409&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034909409&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0034909409

VL - 12

SP - 155

EP - 175

JO - Reviews in Medical Microbiology

JF - Reviews in Medical Microbiology

SN - 0954-139X

IS - 3

ER -